Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 7/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | METAP2 | P50579 | 1/20 | 0.48 |
| ▸ | METAP1 | P53582 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4412612 | 0.95 | HSP90AA1 (0.71) | HSP90AA1MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL4413967 | 0.88 | HSP90AA1 (0.74) | HSP90AA1MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL4411378 | 0.87 | HSP90AA1 (0.68) | HSP90AA1MEN1KMT2AFAAHMAPT | |
| SCHEMBL4407217 | 0.85 | HSP90AA1 (0.65) | HSP90AA1MEN1KMT2AFAAHMAPT | |
| SCHEMBL4422323 | 0.85 | HSP90AA1 (0.68) | HSP90AA1MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL4409573 | 0.84 | FAAH (0.65) | HSP90AA1FAAHMAPTALDH1A1KDM4E | |
| SCHEMBL4410614 | 0.84 | FAAH (0.65) | HSP90AA1FAAHMAPTALDH1A1KDM4E | |
| SCHEMBL4412272 | 0.84 | FAAH (0.65) | HSP90AA1FAAHMAPTALDH1A1KDM4E | |
| SCHEMBL4410939 | 0.84 | FAAH (0.65) | HSP90AA1FAAHMAPTALDH1A1KDM4E | |
| SCHEMBL4410267 | 0.84 | FAAH (0.65) | HSP90AA1FAAHMAPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250844-A1 | Methods of treating cancer using C-4 carbonate taxanes | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-10 | — | — | US | claimed |
| US-6750246-B1 | NOVEL ORALLY ACTIVE PACLITAXEL DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-15 | — | — | US | claimed |
| US-20030220391-A1 | Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-27 | — | — | US | claimed |
| US-20030195226-A1 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | SIT SING-YUEN (US) | 2003-10-16 | — | — | US | claimed |
| US-20090082435-A1 | Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-03-26 | — | — | US | disclosed |
| US-20080103209-A1 | Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-05-01 | — | — | US | disclosed |
| EP-1742626-A2 | COMPOUNDS AND METHODS FOR TREATING NON-INFLAMMATORY PAIN USING PPARALPHA AGONISTS | The Regents of The University of California (US) | 2007-01-17 | — | — | EP | disclosed |
| WO-2006116773-A2 | METHODS, COMPOSITIONS, AND COMPOUNDS FOR MODULATION OF MONOACYLGLYCEROL LIPASE, PAIN, AND STRESS-RELATED DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2005115370-A2 | COMPOUNDS AND METHODS FOR TREATING NON-INFLAMMATORY PAIN USING PPARALPHA AGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050250844-A1 | Methods of treating cancer using C-4 carbonate taxanes | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-10 | — | — | US | disclosed |
| US-6949574-B2 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-27 | — | — | US | disclosed |
| US-6916942-B2 | Process for the preparation of C-4 carbonate taxanes | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-12 | — | — | US | disclosed |
| US-20050131032-A1 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | SIT SING-YUEN (US) | 2005-06-16 | — | — | US | disclosed |
| US-20030195226-A1 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | SIT SING-YUEN (US) | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250844-A1 | Methods of treating cancer using C-4 carbonate taxanes | CA4, CA14, CA13 | HSP90AA1 1867/4885MEN1 1742/4885KMT2A 1489/4885 |
| US-20080103209-A1 | Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists | FAAH, CNR2, FAAH2 | HSP90AA1 616/4885MEN1 4878/4885KMT2A 2333/4885 |
| US-20090082435-A1 | Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders | MGLL, PNLIP, LIPC | HSP90AA1 353/4885MEN1 4743/4885KMT2A 3432/4885 |
| US-20030195226-A1 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | FAAH, FAAH2, NCEH1 | HSP90AA1 1769/4885MEN1 4269/4885KMT2A 1228/4885 |
| US-20050131032-A1 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | FAAH, FAAH2, NCEH1 | HSP90AA1 1769/4885MEN1 4269/4885KMT2A 1228/4885 |
| US-20030220391-A1 | Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability | ABCG2, DPYD, UGT2B7 | HSP90AA1 840/4885MEN1 2570/4885KMT2A 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.